APSR2026-315

Yes
Late-Breaking
Submitted
Poster Presentation
 
AP08-029
P84
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1217705-46904-Case series (841 x 1189 mm) (2)_433742.pdf
Format: PDF Only
06. Tuberculosis
4

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Isman Setiawan * Syarif Hidayatullah State Islamic University Department of Pulmonology and Respiratory Jakarta Indonesia
Neni Sawitri - Dr. M. Goenawan Partowidigdo Lung Hospital Department of Pulmonology and Respiratory Bogor Indonesia
Shabrina Petatriana - Syarif Hidayatullah State Islamic University Department of Pulmonology and Respiratory Jakarta Indonesia
Luthfira Fitri - Dr. M. Goenawan Partowidigdo Lung Hospital Department of Pulmonology and Respiratory Bogor Indonesia
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Isman
Setiawan
ismansetiawan@gmail.com
+628558551419
31-40
Indonesia
Case Report
Management Challenges in Concurrent Drug Resistant Tuberculosis and Lung Adenocarcinoma: A Case Series
Maximum 25 words
Abstract Content
 
 
 
 
The coexistence of tuberculosis (TB) and lung cancer presents significant diagnostic and therapeutic challenges. Drug-resistant TB further complicates management, requiring careful consideration of drug interactions, overlapping toxicities, and optimal treatment sequencing. This case series highlights practical management approaches for patients with concurrent Drug-resistant TB and lung adenocarcinoma.
Case 1 is a 65-year-old woman with stage IIIA (T3N2aM0) right lung adenocarcinoma (EGFR wild-type) with Performance Status (PS) 1, primary rifampicin-resistant (RR) tuberculosis with HIV-negative on the regimen bedaquiline, pretomanid, linezolid, moxifloxacin (BPaLM), and type 2 diabetes mellitus with hypertension. Planned carboplatin-pemetrexed chemotherapy. Case 2 is a 54-year-old man post-right medial lobe lobectomy for lung adenocarcinoma (EGFR wild-type), PS 1, primary Drug Resistant TB on individualized regimen (bedaquiline, levofloxacin, clofazimine, cycloserine, ethambutol). Planned for carboplatin-pemetrexed chemotherapy.
These cases illustrate critical management considerations. First, timing of chemotherapy initiation during anti-TB treatment appears feasible, as all patients achieved sputum conversion and radiographic improvement after 3 months of anti-TB therapy. Second, careful hematologic toxicity monitoring is essential, particularly with linezolid-containing regimens, though concurrent treatment did not increase grade ≥3 adverse events in controlled studies. Third, drug interactions require attention—rifampicin induces hepatic enzymes affecting chemotherapy metabolism, but RR-TB regimens avoid rifampicin, potentially reducing interaction risks. Finally, comorbidities necessitate comprehensive baseline assessments and multidisciplinary coordination. Renal function monitoring is critical for carboplatin dosing, as both cases require creatinine clearance testing before each cycle.
 
 
No
No
 
JPG or JPEG or PNG format ONLY
Drug-resistant tuberculosis, Lung adenocarcinoma, Multidrug therapy
maximum 3 keywords and no abbreviations, separated by commas
Written informed consent was obtained from the patients.
227